Last reviewed · How we verify

DTaP-IPV combined vaccine

Sanofi · Phase 3 active Biologic

DTaP-IPV combined vaccine is a Combination vaccine Biologic drug developed by Sanofi. It is currently in Phase 3 development for Prevention of diphtheria in infants and children, Prevention of tetanus in infants and children, Prevention of pertussis (whooping cough) in infants and children. Also known as: TETRAXIM™: Diphtheria, Tetanus, Polio, Acellular Pertussis.

This combined vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, and poliovirus by delivering inactivated toxins and viral antigens.

This combined vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, and poliovirus by delivering inactivated toxins and viral antigens. Used for Prevention of diphtheria in infants and children, Prevention of tetanus in infants and children, Prevention of pertussis (whooping cough) in infants and children.

At a glance

Generic nameDTaP-IPV combined vaccine
Also known asTETRAXIM™: Diphtheria, Tetanus, Polio, Acellular Pertussis
SponsorSanofi
Drug classCombination vaccine
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease Prevention
PhasePhase 3

Mechanism of action

DTaP-IPV is a combination immunization that contains diphtheria and tetanus toxoids (inactivated bacterial toxins), acellular pertussis antigen, and inactivated poliovirus particles. Upon administration, these antigens trigger both humoral (antibody) and cell-mediated immune responses, priming the immune system to recognize and neutralize these pathogens if encountered naturally. This provides protection against four serious infectious diseases in a single vaccine formulation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about DTaP-IPV combined vaccine

What is DTaP-IPV combined vaccine?

DTaP-IPV combined vaccine is a Combination vaccine drug developed by Sanofi, indicated for Prevention of diphtheria in infants and children, Prevention of tetanus in infants and children, Prevention of pertussis (whooping cough) in infants and children.

How does DTaP-IPV combined vaccine work?

This combined vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, and poliovirus by delivering inactivated toxins and viral antigens.

What is DTaP-IPV combined vaccine used for?

DTaP-IPV combined vaccine is indicated for Prevention of diphtheria in infants and children, Prevention of tetanus in infants and children, Prevention of pertussis (whooping cough) in infants and children, Prevention of poliomyelitis in infants and children.

Who makes DTaP-IPV combined vaccine?

DTaP-IPV combined vaccine is developed by Sanofi (see full Sanofi pipeline at /company/sanofi).

Is DTaP-IPV combined vaccine also known as anything else?

DTaP-IPV combined vaccine is also known as TETRAXIM™: Diphtheria, Tetanus, Polio, Acellular Pertussis.

What drug class is DTaP-IPV combined vaccine in?

DTaP-IPV combined vaccine belongs to the Combination vaccine class. See all Combination vaccine drugs at /class/combination-vaccine.

What development phase is DTaP-IPV combined vaccine in?

DTaP-IPV combined vaccine is in Phase 3.

What are the side effects of DTaP-IPV combined vaccine?

Common side effects of DTaP-IPV combined vaccine include Injection site pain, redness, or swelling, Fever, Irritability or fussiness, Drowsiness, Loss of appetite.

Related